Skip to main content

Table 1 Summary of studies included in the quantitative analysis

From: Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

    N %
Total number of studies included 96  
   Original articles 82 85.4
   Abstracts 14 14.6
Year of publication
   2009 6 6.3
   2010 7 7.3
   2011 8 8.3
   2012 12 12.5
   2013 17 17.7
   2014 29 30.2
   2015 17 17.7
Global distribution of location of institutions of selected studies
   North America 54 56.3
   Europe 21 21.9
   Asia 18 18.7
   Australia/Africa/South America (1 each) 3 3.1
Single vs multi-institutional
   Single institution 83 86.5
   Multi-institutional 13 13.5
Type of study
   Retrospective series 54 56.3
   Phase 2 studies 22 22.9
   Prospective series 11 11.5
   Phase 1 studies 5 5.2
   Phase 1/2 studies 3 3.1
   Phase 3 studies 1 1
Criteria for resectability
   NCCN/AHPBA/SSO/SSAT consensus 38 39.6
   MD Anderson 8 8.3
   Other 29 30.2
   Not mentioned 21 21.9
Number of studies of each local/anatomical stage
   Resectable 18 18.8
   Borderline resectable (BR) 15 15.6
   Locally advanced unresectable (LA) 29 30.2
   R + BR 5 5.2
   BR + LA 24 25
   R + BR + LA 5 5.2
Number of patients in each anatomical stage
   Resectable 1056 19.1
   Borderline resectable (BR) 935 16.9
   Locally advanced unresectable (LA) 1840 33.3
   R + BR 202 3.7
   BR + LA 1014 18.4
   R + BR + LA 473 8.6
Criteria for of radiology response assessment
   RECIST 48 50
   WHO 5 5.2
   Other 2 2.1
   Not mentioned 41 42.7
Criteria for toxicity assessment
   NCI CTCAE 43 44.8
   WHO 5 5.2
   RTOG 2 2.1
   Not mentioned/not applicable 46 47.9
Type of neoadjuvant therapy
   Chemoradiotherapy 33 34.4
   Chemotherapy alone 20 20.8
   Chemotherapy with chemoradiation 41 42.7
   Radiation alone 2 2.1
Chemotherapy drugs
   Monotherapy (Gem/5FU/Cape/UFT/Cis) 26 27.1
   FOLFIRINOX 20 20.8
   Gemcitabine + oxaliplatin* 8 8.3
   Gemcitabine or 5FU + cisplatin 7 7.3
   Gemcitabine + Docetaxel 3 3.1
   GTX (gemcitabine, taxane, capecitabine) 6 6.3
   Gem + biologic (bevacizumab, cetuximab) 3 3.1
   Gem + S1 5 5.2
   Gem + Nab-paclitaxel 2 2.1
   5FU + cisplatin + interferon 1 1
   Multiple 11 11.5
   Not mentioned 2 2.1
  None 2 2.1
Radiotherapy
   Yes 76 79.2
   No 20 20.8
  1. *Includes one study with gemcitabine + oxaliplatin + cetuximab
  2. R resectable, BR borderline resectable, LA locally advanced, Gem Gemcitabine, Cape capecitabine, 5FU 5 Fluorouracil, UFT uracil/tegafur